| Name | Title | Contact Details |
|---|
Discovery Life Sciences, the Biospecimen and Biomarker Specialists™, is a leading provider of highly characterized human biospecimens and cellular starting materials integrated with expert multi-omic analytical services to advance cell and gene therapy and precision medicine programs for cancer, infectious disease, and other complex conditions. Our robust biospecimen and biomarker platform is optimized for speed and large scale capacity. We routinely manage hundreds of studies and expertly test thousands of biospecimens simultaneously as a single vendor - eliminating time consuming and inefficient transfers of biospecimens or data between different vendors. We offer one of the largest recallable donor pools, Research Use Only (RUO) and clinical-grade (GMP) fresh and cryopreserved human cellular materials to support cell and gene therapy programs at any scale from start to finish. Leading biopharma, diagnostic and academic institutions trust us to quickly deliver high-quality biospecimens and reliable, reproducible biomarker data, so they can outpace their competition and push the leading edge of innovation.
VBI Vaccines Inc.is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology.
H and R Healthcare Inc is a Lakewood, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bamboo was formed to advance the work of Dr. Richard Jude Samulski, the Director of the Gene Therapy Center at the University of North Carolina (UNC), from the laboratory into human clinical trials where it could meet the requirements for drug approval. Dr. Samulski is a pioneer in the field of gene therapy. Over thirty (30) years ago, Dr. Samulski was the first person to realize the potential to use the adeno-associated virus (AAV) as a vehicle to replace a defective gene with a healthy gene. Since that time, he has re-engineered the naturally occurring virus to target delivery to certain tissues, de-target other tissues, and improve its safety. This has resulted in over twenty (20) patents related to the use of AAV for therapeutic uses. Dr. Samulski continues to lead innovation in the field of vector optimization and AAV re-engineering.
The THOR Group is a Manhattan Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.